Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PARPs and ADP-ribosyl hydrolases in cancer therapy: From drug targets to biomarkers

24 Jun 2025

Abstract excerpt

The PARP family of enzymes catalyzes ADP-ribosylation, a modification of macromolecules, and plays a crucial role in DNA damage repair. The landmark discovery that cancer cells deficient in homologous recombination repair are highly sensitive to PARP inhibitors has paved the way for the clinical success of multiple PARP inhibitors in the treatment of breast, ovarian, pancreatic, and prostate cancers. This...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Calcium signaling and nucleotide metabolism
Share to PARP inhibition in cancer therapy
Share to Toxin Mechanisms and Immunotoxins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40580812
DOI: 10.1016/j.dnarep.2025.103863

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PARPs and ADP-ribosyl hydrolases in cancer therapy: From drug targets to biomarkersPMID 40580812Read ↗

PARP (Poly ADP‐ribose Polymerase) Family in Health and DiseaseSemantic proximity Read ↗

Poly (ADP-ribose) polymerase inhibitors in cancer therapySemantic proximity Read ↗

The PARP Enzyme Family and the Hallmarks of Cancer Part 2: Hallmarks Related to Cancer Host InteractionsSemantic proximity Read ↗

Histone ADP-ribosylation promotes resistance to PARP inhibitors by facilitating PARP1 release from DNA lesionsSemantic proximity Read ↗

Review of Poly (ADP-ribose) Polymerase (PARP) Mechanisms of Action and Rationale for Targeting in Cancer and Other DiseasesSemantic proximity Read ↗

Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer TherapySemantic proximity Read ↗

Trial watch – inhibiting PARP enzymes for anticancer therapySemantic proximity Read ↗

Targeting DNA repair pathways: mechanisms and potential applications in cancer therapySemantic proximity Read ↗

PARP inhibitors in gastric cancer: beacon of hopeSemantic proximity Read ↗

Mechanisms of PARP inhibitor resistance in cancer and insights into the DNA damage responseSemantic proximity Read ↗

Integrated, Integral, and Exploratory Biomarkers in the Development of Poly(ADP-Ribose) Polymerase Inhibitors.Semantic proximity Read ↗

Beyond PARP1: The Potential of Other Members of the Poly (ADP-Ribose) Polymerase Family in DNA Repair and Cancer TherapeuticsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.